FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034673683> ?p ?o ?g. }

• W2034673683 endingPage "145" @default.
• W2034673683 startingPage "137" @default.
• W2034673683 abstract "Because of its known heterogeneity, the analysis of antigen expression is crucial prior to the initiation of antigen-specific immunotherapy for melanoma. The melanoma differentiation antigens gp100, MART-1 and tyrosinase are involved in a common pathway of melanin synthesis. Peptides derived from these melanoma differentiation antigens are used in the immunotherapy of melanoma and antibodies recognizing these antigens are commonly applied to detect melanocytic lesions. One hundred and ninety-one paraffin-embedded melanoma metastases from 28 patients with 2–19 lesions (mean, 6.8) developing synchronously (n=67) or asynchronously (n=124) were analysed by immunohistochemistry for the expression of the melanoma differentiation antigens, as well as cancer/testis antigens of the melanoma antigen-A (MAGE-A) family (monoclonal antibodies 77B and 57B), anti-S100 and SM5-1. The overall reactivities were 81.6% (gp100), 79.5% (MART-1), 59.6% (tyrosinase), 59.1% (77B), 60.7% (57B), 93.2% (S100) and 91.6% (SM5-1). Twenty-seven lesions (14.1%) were positive for all tumour-associated antigens, 75 lesions (39.2%) were negative for one antigen and 87 lesions (45.5%) were negative for several tumour-associated antigens. Co-ordinated loss was found for lesions negative for gp100 and MART-1 (9.4%, P<0.0005), gp100 and tyrosinase (11.0%, P=0.009), MART-1 and tyrosinase (15.2%, P<0.0005) and gp100, MART-1 and tyrosinase (8.9%, P<0.0005), which is up to six times higher than the expected calculated loss. This co-ordinated loss of melanoma differentiation antigens in melanoma did not include cancer testis antigens and S100 or SM5-1. On average, the melanoma differentiation antigens stained 50–65% of cells within a lesion, and 10–39% of synchronous clusters were heterogeneous for melanoma differentiation antigen expression. In conclusion, broader polypeptide vaccines should be used for melanoma immunotherapy." @default.
• W2034673683 created "2016-06-24" @default.
• W2034673683 creator A5015624855 @default.
• W2034673683 creator A5018780132 @default.
• W2034673683 creator A5038497681 @default.
• W2034673683 creator A5065762235 @default.
• W2034673683 creator A5077885692 @default.
• W2034673683 creator A5079138849 @default.
• W2034673683 creator A5088408264 @default.
• W2034673683 date "2006-04-01" @default.
• W2034673683 modified "2023-10-02" @default.
• W2034673683 title "Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy" @default.
• W2034673683 cites W1572267688 @default.
• W2034673683 cites W1965708703 @default.
• W2034673683 cites W1984869659 @default.
• W2034673683 cites W1985149018 @default.
• W2034673683 cites W1986019318 @default.
• W2034673683 cites W1988657320 @default.
• W2034673683 cites W1989150855 @default.
• W2034673683 cites W1993041599 @default.
• W2034673683 cites W2001157494 @default.
• W2034673683 cites W2001280122 @default.
• W2034673683 cites W2009801524 @default.
• W2034673683 cites W2012986020 @default.
• W2034673683 cites W2020631843 @default.
• W2034673683 cites W2036063900 @default.
• W2034673683 cites W2036500143 @default.
• W2034673683 cites W2042708866 @default.
• W2034673683 cites W2045642969 @default.
• W2034673683 cites W2049998759 @default.
• W2034673683 cites W2051182199 @default.
• W2034673683 cites W2052069700 @default.
• W2034673683 cites W2053376515 @default.
• W2034673683 cites W2057306342 @default.
• W2034673683 cites W2062376829 @default.
• W2034673683 cites W2066960417 @default.
• W2034673683 cites W2088342139 @default.
• W2034673683 cites W2104401164 @default.
• W2034673683 cites W2116293732 @default.
• W2034673683 cites W2154298769 @default.
• W2034673683 cites W2164584613 @default.
• W2034673683 cites W2165951569 @default.
• W2034673683 cites W2166630161 @default.
• W2034673683 cites W2319070997 @default.
• W2034673683 cites W37316445 @default.
• W2034673683 doi "https://doi.org/10.1097/01.cmr.0000200489.55099.20" @default.
• W2034673683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16567969" @default.
• W2034673683 hasPublicationYear "2006" @default.
• W2034673683 type Work @default.
• W2034673683 sameAs 2034673683 @default.
• W2034673683 citedByCount "26" @default.
• W2034673683 countsByYear W20346736832012 @default.
• W2034673683 countsByYear W20346736832013 @default.
• W2034673683 countsByYear W20346736832015 @default.
• W2034673683 countsByYear W20346736832017 @default.
• W2034673683 countsByYear W20346736832018 @default.
• W2034673683 countsByYear W20346736832019 @default.
• W2034673683 countsByYear W20346736832020 @default.
• W2034673683 countsByYear W20346736832021 @default.
• W2034673683 countsByYear W20346736832022 @default.
• W2034673683 countsByYear W20346736832023 @default.
• W2034673683 crossrefType "journal-article" @default.
• W2034673683 hasAuthorship W2034673683A5015624855 @default.
• W2034673683 hasAuthorship W2034673683A5018780132 @default.
• W2034673683 hasAuthorship W2034673683A5038497681 @default.
• W2034673683 hasAuthorship W2034673683A5065762235 @default.
• W2034673683 hasAuthorship W2034673683A5077885692 @default.
• W2034673683 hasAuthorship W2034673683A5079138849 @default.
• W2034673683 hasAuthorship W2034673683A5088408264 @default.
• W2034673683 hasConcept C147483822 @default.
• W2034673683 hasConcept C159654299 @default.
• W2034673683 hasConcept C181199279 @default.
• W2034673683 hasConcept C203014093 @default.
• W2034673683 hasConcept C204232928 @default.
• W2034673683 hasConcept C2777658100 @default.
• W2034673683 hasConcept C2777701055 @default.
• W2034673683 hasConcept C502942594 @default.
• W2034673683 hasConcept C542903549 @default.
• W2034673683 hasConcept C55493867 @default.
• W2034673683 hasConcept C71924100 @default.
• W2034673683 hasConcept C86803240 @default.
• W2034673683 hasConcept C87554066 @default.
• W2034673683 hasConcept C8891405 @default.
• W2034673683 hasConceptScore W2034673683C147483822 @default.
• W2034673683 hasConceptScore W2034673683C159654299 @default.
• W2034673683 hasConceptScore W2034673683C181199279 @default.
• W2034673683 hasConceptScore W2034673683C203014093 @default.
• W2034673683 hasConceptScore W2034673683C204232928 @default.
• W2034673683 hasConceptScore W2034673683C2777658100 @default.
• W2034673683 hasConceptScore W2034673683C2777701055 @default.
• W2034673683 hasConceptScore W2034673683C502942594 @default.
• W2034673683 hasConceptScore W2034673683C542903549 @default.
• W2034673683 hasConceptScore W2034673683C55493867 @default.
• W2034673683 hasConceptScore W2034673683C71924100 @default.
• W2034673683 hasConceptScore W2034673683C86803240 @default.
• W2034673683 hasConceptScore W2034673683C87554066 @default.
• W2034673683 hasConceptScore W2034673683C8891405 @default.
• W2034673683 hasIssue "2" @default.

• next